X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (58) 58
index medicus (48) 48
hepatitis c, chronic - drug therapy (42) 42
ribavirin (42) 42
peginterferon alpha (41) 41
antiviral agents - therapeutic use (40) 40
male (38) 38
middle aged (33) 33
adult (32) 32
female (32) 32
gastroenterology & hepatology (32) 32
drug therapy, combination (31) 31
hepatitis c (30) 30
interferon-alpha - therapeutic use (26) 26
hepatitis c virus (24) 24
treatment outcome (24) 24
interferon (22) 22
ribavirin - therapeutic use (22) 22
peginterferon-alpha (19) 19
polyethylene glycols - therapeutic use (19) 19
genotype (18) 18
pharmacology & pharmacy (17) 17
therapy (17) 17
aged (16) 16
chronic hepatitis c (16) 16
virus-infection (16) 16
antiviral agents - administration & dosage (14) 14
antiviral agents - adverse effects (14) 14
combination therapy (14) 14
recombinant proteins (14) 14
infectious diseases (13) 13
hepacivirus - genetics (12) 12
biological response modifiers (11) 11
hepatitis (11) 11
interferon-alpha - adverse effects (11) 11
ribavirin - administration & dosage (11) 11
sustained virological response (11) 11
virology (11) 11
combination (10) 10
hepatitis c, chronic - complications (10) 10
hepatitis c, chronic - virology (10) 10
liver (10) 10
plus ribavirin (10) 10
ribavirin - adverse effects (10) 10
viral load (10) 10
virus diseases (10) 10
cirrhosis (9) 9
health aspects (9) 9
hepacivirus - drug effects (9) 9
randomized-trial (9) 9
recombinant proteins - therapeutic use (9) 9
analysis (8) 8
antiviral therapy (8) 8
care and treatment (8) 8
chronic hepatitis b (8) 8
daclatasvir (8) 8
efficacy (8) 8
hcv (8) 8
infection (8) 8
interferon-alpha - administration & dosage (8) 8
pegylated interferon (8) 8
sofosbuvir (8) 8
trial (8) 8
young adult (8) 8
antiviral agents (7) 7
chronic hepatitis-c (7) 7
genetic aspects (7) 7
hepatocellular-carcinoma (7) 7
infections (7) 7
initial treatment (7) 7
patients (7) 7
polyethylene glycols (7) 7
polyethylene glycols - administration & dosage (7) 7
prospective studies (7) 7
treatment-naive patients (7) 7
alpha-2b plus ribavirin (6) 6
anemia (6) 6
asunaprevir (6) 6
chronic infection (6) 6
drug therapy (6) 6
fibrosis (6) 6
interferon alpha-2 (6) 6
interferon-alpha (6) 6
lamivudine (6) 6
microbiology (6) 6
peginterferon alpha-2a (6) 6
peginterferon alpha-2b (6) 6
peginterferon-α (6) 6
polyethylene glycols - adverse effects (6) 6
retrospective studies (6) 6
telaprevir (6) 6
time factors (6) 6
chronic hcv infection (5) 5
cohort studies (5) 5
digestive system diseases (5) 5
epidemiology (5) 5
genotypes (5) 5
hcv genotype 1 (5) 5
hdv (5) 5
hepacivirus - classification (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Hepatology, ISSN 0270-9139, 04/2015, Volume 61, Issue 4, pp. 1109 - 1111
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 05/2007, Volume 22, Issue 5, pp. 645 - 652
Background:  The efficacy and safety of peginterferon alpha‐2a (40 KD) (peg‐IFNα‐2a) plus ribavirin has not been reported for Japanese patients with chronic... 
ribavirin | Japanese | peginterferon alpha‐2a | hepatitis C | genotype | Genotype | Peginterferon alpha-2a | Hepatitis C | Ribavirin
Journal Article
by Zhang, L and Li, H and Ren, H and Hu, P
MOLECULAR IMMUNOLOGY, ISSN 0161-5890, 11/2018, Volume 103, pp. 270 - 278
Given the B helper function of follicular T helper (Tfh) cells and peripheral T helper (Tph) cells, we researched the roles of circulating... 
Hepatitis B surface antigen | VIRUS-INFECTION | SEROCONVERSION | MANAGEMENT | HBEAG | QUANTIFICATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | Follicular T helper cells | Peripheral T helper cells | IMMUNOLOGY | SUBSET | BENEFIT | DISEASE | FREQUENCY | Peginterferon-alpha | Hepatitis B virus | PD-1
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 07/2019, Volume 26, Issue S1, pp. 50 - 58
Although long‐term antiviral treatment with nucleos(t)ide analogs (NAs) can lead to histological improvement in patients with chronic hepatitis B (CHB), a... 
chronic hepatitis B | histopathology | nucleos(t)ide analog | peginterferon alpha | ENTECAVIR | CLEARANCE | INFECTIOUS DISEASES | PEGYLATED INTERFERON ALPHA-2A | SEROCONVERSION | COMBINATION THERAPY | LAMIVUDINE | VIROLOGY | REDUCTION | VIRUS INFECTION | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | ANTIGEN
Journal Article
Journal Article
영남의대학술지, ISSN 1225-7737, 2016, Volume 33, Issue 2, pp. 150 - 154
Hepatitis C virus (HCV) infection is present in a high proportion of patients with kidney transplantation. Compared with uninfected kidney transplant... 
Peginterferon alpha | Chronic hepatitis C | Ribavirin | Kidney transplantation
Journal Article
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 09/2016, Volume 44, Issue 6, pp. 620 - 628
Summary Background Therapy of chronic hepatitis D with Interferon is successful when testing for HDV‐RNA turns negative. This end‐point is disputed. Aim To... 
D VIRUS | HDV RNA RELAPSE | DELTA INFECTION | PEGINTERFERON ALPHA | PEGYLATED INTERFERON | HBV-DNA | HBEAG-NEGATIVE PATIENTS | PHARMACOLOGY & PHARMACY | GASTROENTEROLOGY & HEPATOLOGY | Interferon | RNA | Biological response modifiers | Coronary heart disease
Journal Article
World Journal of Gastroenterology, ISSN 1007-9327, 09/2006, Volume 12, Issue 34, pp. 5554 - 5556
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2015, Volume 61, Issue 5, pp. 817 - 825
Journal Article
by Yu, ML
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, ISSN 0815-9319, 08/2017, Volume 32, Issue 8, pp. 1436 - 1442
Peginterferon/ribavirin has been the standard-of-care for chronic hepatitis C virus (HCV) infections: 48 weeks for genotype 1 or 4 (HCV-1/4) and 24 weeks for... 
APASL CONSENSUS STATEMENTS | TREATMENT DURATION | DAA | resource | LEDIPASVIR-SOFOSBUVIR | VIRUS GENOTYPE 1 | DACLATASVIR PLUS ASUNAPREVIR | IFN | SUSTAINED VIROLOGICAL RESPONSE | TREATMENT-NAIVE | TREATMENT-EXPERIENCED PATIENTS |